Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $30.00
D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price target decreased by Chardan Capital from $39.00 to $30.00 in a report released on Tuesday,Benzinga reports. Chardan Capital currently ...
HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)
D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at ...
AI Uncovers Hidden Genetic Clues That Challenge COVID-19’s Origins
A surprising new study suggests that COVID-19 may not have originated from bats or pangolins, but rather from a rare fusion ...
eLife4d
Maturation and detoxification of synphilin-1 inclusion bodies regulated by sphingolipids
Due to proteostasis stress induced by aging or disease, misfolded proteins can form toxic intermediate species of aggregates and eventually mature into less toxic inclusion bodies (IBs). Here, using a ...
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts
In the assessment of 12-month price targets, analysts unveil insights for 4D Molecular Therapeutics, presenting an average ...